{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107013","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.989681+00:00","generated_at":"2026-05-17T00:11:38.999681+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CVRx Q3 2025 revenue $14.7M (+10% YoY), net loss $12.9M; CMS approves favorable CPT codes for 2026","bullets":["Total revenue $14.7M, up 10% YoY; U.S. revenue $13.5M (+10%); Europe revenue $1.2M (+12%).","Net loss $12.9M ($0.49/share) vs $13.1M ($0.57/share) in Q3 2024; per-share loss improved.","U.S. active implanting centers reached 250, up 20% year-over-year.","CMS finalized Category I CPT codes for Barostim, improving patient access and removing adoption barriers.","FY2025 guidance: revenue $55.6M-$56.6M (narrowed from $55M-$57M), gross margin 85%-86% (raised from 83%-84%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107013","json":"https://secwatch.observer/filing/0001104659-25-107013.json","markdown":"https://secwatch.observer/filing/0001104659-25-107013.md","text":"https://secwatch.observer/filing/0001104659-25-107013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925107013/0001104659-25-107013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925107013/tm2530302d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:11:38.999681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}